Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jack

Showing results (531-540 of 594) with videos related to

Pageof 60
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2022
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell CarcinomaTrisha M Wise-Draper, Shuchi Gulati, Sarah Palackdharry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLCKaiwen Wang, Robyn Du, Nathaniel J Myall, et al.
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Carcinogenesis|April 2, 2005
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer typesAmanda Ewart-Toland, Qi Dai, Yu-Tang Gao, et al.
JAMA Oncology|November 6, 2015
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical TrialWilliam N William, Vassiliki Papadimitrakopoulou, J Jack Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|May 22, 2026
Long-term outcomes after proton therapy vs. intensity-modulated photon radiotherapy with concurrent chemotherapy for locally advanced non-small-cell lung cancer: post-hoc analysis of a prospective randomized trialTingshi Su, Ting Xu, Mei Chen, et al.
The Oncologist|May 8, 2023
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center ExperienceMehmet Altan, Felipe Soto, Linda L Zhong, et al.
Cancers|January 8, 2023
Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19Muhammad Aminu, Divya Yadav, Lingzhi Hong, et al.
Nature Medicine|January 16, 2026
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trialAnna Morena D'Alise, Jason Willis, Fahriye Duzagac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLCFederica Pecci, Hui Li, Alessandro Di Federico, et al.
Pageof 60

Showing results (531-540 of 594) with videos related to

Sort By:
Pageof 60
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2022
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell CarcinomaTrisha M Wise-Draper, Shuchi Gulati, Sarah Palackdharry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLCKaiwen Wang, Robyn Du, Nathaniel J Myall, et al.
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Carcinogenesis|April 2, 2005
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer typesAmanda Ewart-Toland, Qi Dai, Yu-Tang Gao, et al.
JAMA Oncology|November 6, 2015
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical TrialWilliam N William, Vassiliki Papadimitrakopoulou, J Jack Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|May 22, 2026
Long-term outcomes after proton therapy vs. intensity-modulated photon radiotherapy with concurrent chemotherapy for locally advanced non-small-cell lung cancer: post-hoc analysis of a prospective randomized trialTingshi Su, Ting Xu, Mei Chen, et al.
The Oncologist|May 8, 2023
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center ExperienceMehmet Altan, Felipe Soto, Linda L Zhong, et al.
Cancers|January 8, 2023
Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19Muhammad Aminu, Divya Yadav, Lingzhi Hong, et al.
Nature Medicine|January 16, 2026
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trialAnna Morena D'Alise, Jason Willis, Fahriye Duzagac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLCFederica Pecci, Hui Li, Alessandro Di Federico, et al.
Pageof 60